HIV/AIDS research

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

National Week of Prayer for the Healing of AIDS Streaming Discussion Series Centers Black Americans

Retrieved on: 
Tuesday, February 20, 2024

RICHMOND, Va., Feb. 20, 2024 /PRNewswire/ -- The National Week of Prayer for the Healing of AIDS, taking place March 3-9, will feature streaming discussions focusing on HIV/AIDS and Black Americans.

Key Points: 
  • RICHMOND, Va., Feb. 20, 2024 /PRNewswire/ -- The National Week of Prayer for the Healing of AIDS, taking place March 3-9, will feature streaming discussions focusing on HIV/AIDS and Black Americans.
  • National Week of Prayer for the Healing of AIDS, live streaming series, March 4-6, 2024.
  • Despite significant advances in HIV prevention and treatment methods, Black Americans represent 43% of new HIV diagnoses even though they are just 12% of the population.
  • The Balm In Gilead, Inc. is a 36-year-old organization whose mission is to equip faith communities serving Black Americans to become community hubs for health awareness, education, and support.

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

George Washington University to Host Webinar on Culturally Responsive Communication

Retrieved on: 
Wednesday, September 6, 2023

WASHINGTON, Sept. 6, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on September 20 to discuss culturally responsive communication with patients. The webinar is a part of a training series for the Two in One: HIV + COVID Screening and Testing Model, a national medical education program, and will feature Adedotun Ogunbajo, PhD, of Harvard's Center for Population and Development Studies and Elder George Kerr III of the Washington D.C. Center for AIDS Research.

Key Points: 
  • WASHINGTON, Sept. 6, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on September 20 to discuss culturally responsive communication with patients.
  • "For the Two in One program's second webinar on the topic of culturally responsive communication, we will emphasize how clinicians can share power with patients," said Maranda Ward, EdD, MPH, principal investigator of the Two in One Model and assistant professor of clinical research and leadership at GW SMHS.
  • "In addition to discussing ways to facilitate culturally responsive communication, we will review what sharing power in the clinician-patient interaction looks like."
  • The event is entitled "Culturally Responsive Communication, Part II: Sharing Power with Patients," and is scheduled for September 20, from 12 p.m. – 1 p.m.

ACTG Announces Publication of REPRIEVE Trial in New England Journal of Medicine and Presentation at IAS 2023

Retrieved on: 
Monday, July 24, 2023

Today’s publication coincides with the symposium “The REPRIEVE trial: Developing a Cardiovascular Disease Prevention Strategy for People Living with HIV,” taking place today at IAS 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia.

Key Points: 
  • Today’s publication coincides with the symposium “The REPRIEVE trial: Developing a Cardiovascular Disease Prevention Strategy for People Living with HIV,” taking place today at IAS 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia.
  • “REPRIEVE is an extraordinarily important study because it addresses the need for interventions to prevent cardiovascular events in people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • The 35 percent reduction in MACE was consistent across key study groups, including sex, race, and global burden of disease region.
  • These conclusions are based on a review of the data by an Independent Data and Safety Monitoring Board, which stopped the trial early.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 28, 2023

BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.
  • The findings of the human and preclinical studies suggest that CPI-818 enhances anti-tumor immunity representing a potentially novel approach to immunotherapy.
  • In the fourth quarter of 2022, the decrease of $0.7 million was primarily related to a decrease in personnel costs.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2022 financial results.

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

Retrieved on: 
Monday, February 27, 2023

ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.

Key Points: 
  • The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.
  • The data indicated very high levels of immunogenicity of the treatment, particularly the induction of T cell immunity, even though HIV infection compromises the immune system.
  • “The GeoVax MVA62B was previously tested in multiple clinical trials as a component of vaccine regimens designed to induce immune responses that prevent HIV infection.
  • We are continuing development of the GeoVax MVA-VLP vaccine platform targeting multiple viral diseases, including COVID-19, MPOX, Smallpox and hemorrhagic fever viruses, such as Lassa Fever and Ebola.”

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

Retrieved on: 
Tuesday, February 21, 2023

These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.

Key Points: 
  • These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program.
  • Findings from the HIV cure research program include results from three studies evaluating strategies to maintain virologic control in the absence of ART.
  • “Gilead will continue exploring novel combination strategies in our pursuit to help end the HIV epidemic for everyone, everywhere.”
    Curing HIV remains the ultimate aspiration of Gilead’s HIV research and development efforts.
  • Gilead has a comprehensive cure research and development program that is advancing with speed and conviction.

Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy

Retrieved on: 
Thursday, January 19, 2023

Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.

Key Points: 
  • Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.
  • “This grant to Dr. Montaner is the latest of several awards we have made to outstanding scientists at The Wistar Institute,” said Dr. Rowena Johnston, amfAR’s Vice President and Director of Research.
  • These strategies will be combined and tested in mouse models with functional human immune cells able to support HIV infection.
  • The Montaner lab and other groups in the BEAT-HIV Collaboratory were awarded a five-year award from the NIH last year.

CLARKE DESIGN WELCOMES BRANDING & MARKETING EXECUTIVE ANNMARI SHANNAHAN AS PARTNER

Retrieved on: 
Wednesday, December 7, 2022

NEW YORK, Dec. 7, 2022 /PRNewswire/ -- CLARKE, a creative agency focused on bringing brand visions, voices, and visuals to life has tapped marketing executive AnnMari Shannahan to join its leadership as a partner. She brings over three decades of experience and expertise in leading teams to deliver for global brands.

Key Points: 
  • NEW YORK, Dec. 7, 2022 /PRNewswire/ -- CLARKE , a creative agency focused on bringing brand visions, voices, and visuals to life has tapped marketing executive AnnMari Shannahan to join its leadership as a partner.
  • As the agency enters its 14th year, Founder and Creative Director Michael Clarke wanted to scale the business yet stay true to the firm's core principles.
  • "Her deep marketing experience will be of enormous value as we continue to be guided by the desire to create positive change with design."
  • "Clarke's leading design principle is understanding the "why" and "how" as much as the "what"," said Shannahan.